The IP & Science business of Thomson Reuters, US, has announced the release of a life sciences report, 'An Outlook on U.S. Biosimilar Competition.' The report seeks to provide a comprehensive view of the challenges facing companies entering the US biosimilar drug market and key players predicted to break into this developing pharmaceutical space.
While the US continues to take steps toward entering the global biosimilar market, it reportedly lags behind other nations in this space. The report compares US and EU regulations to underscore the significant differences between these regions and explore ways the US can compete more effectively, in addition to reviewing emerging regulatory developments in India and China. It also identifies potential leaders of the US market, including Amgen, Hospira and Sandoz, among the top three pharmaceutical companies with the most potential to dominate the early stages of biosimilar medications entering the US.
'An Outlook on U.S. Biosimilar Competition' was created by Thomson Reuter's experts in generic drug and API intelligence. The team utilised Newport Premium, the industry's leading tool for identifying and evaluating generic drug development and licensing opportunities, to compile the report.
